This program was approved by the IASLC 2021 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2021 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

WEDNESDAY, SEPTEMBER 8, 202112:00 – 13:00 MDT / 14:00 – 15:00 EDT

20:00 – 21:00 CEST

WHO SHOULD ATTEND? This activity is intended for medical oncology, pathology, and pulmonology clinicians attending the virtual IASLC 2021 World Conference on Lung Cancer meeting and who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

EXPERT FACULTY

Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO (Chair)Li Shu Fan Medical Foundation Professor, Clinical OncologyThe Chinese University of Hong KongHong Kong, China

Shirish M. Gadgeel, MDChief, Division of Hematology and Oncology Department of Internal MedicineHenry Ford Cancer Institute/Henry Ford Health SystemDetroit, MI

Antonio Passaro, MD, PhDMedical Oncologist, Division of Thoracic OncologyEuropean Institute of OncologyMilan, Italy

EDUCATIONAL OBJECTIVESUpon completion of this activity, participants should be better able to:

• Analyze the predictive/prognostic significance of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC)

• Apply optimal diagnostic strategies for identifying NSCLC with EGFR exon 20 insertions

• Assess clinical trial data regarding new and emerging treatment options for advanced NSCLC with EGFR exon 20 insertions

• Employ appropriate techniques to manage adverse events associated with EGFR inhibition

PROGRAM AGENDA

12:00 – 12:05 MDT Welcome and Introductions Prof. Tony S.K. Mok (Chair)

12:05 – 12:20 MDT EGFR Insertion Mutations in NSCLC: Why and How Do We Test? Dr. Shirish M. Gadgeel

12:20 – 12:40 MDT New and Emerging Therapies for NSCLC with EXON 20 INS Mutations Prof. Tony S.K. Mok (Chair)

12:40 – 12:50 MDT Managing Toxicity with Anti-EGFR Exon 20 Agents Dr. Antonio Passaro

12:50 – 13:00 MDT Audience Q&A and Closing Remarks All Faculty

©2021 RMEI Medical Education, LLC | All Rights Reserved | 62-21-648-WC

JOINT ACCREDITATION STATEMENTIn support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to

provide continuing education for the healthcare team.

Credit Designation RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPSRMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationship for all persons in control of content before the learner engages in the education.

FEE INFORMATIONThere is no fee for this educational activity. Individuals must be registered for the IASLC 2021 WCLC in order to attend this symposium.

Provided by RMEI Medical Education, LLC. Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Targeting EGFR Exon 20 Insertions in NSCLC:Current and Future Prospects

SATELLITE CME SYMPOSIUM